Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Dna Repair Drug Focus On Parp Inhibitors Market

ID: MRFR/Pharma/38241-HCR
100 Pages
Rahul Gotadki
Last Updated: April 24, 2026

DNA Repair Drug Focus on PARP Inhibitors Market Research Report By Mechanism of Action (PARP Inhibition, DNA Damage Response, Cell Cycle Checkpoint Regulation), By Administration Route (Oral, Intravenous, Subcutaneous), By Indication (Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer), By Therapeutic Area (Oncology, Hematology, Genetic Disorders) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Dna Repair Drug Focus On Parp Inhibitors Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Mechanism of Action (USD Billion)
  49.     4.1.1 PARP Inhibition
  50.     4.1.2 DNA Damage Response
  51.     4.1.3 Cell Cycle Checkpoint Regulation
  52.   4.2 Healthcare, BY Administration Route (USD Billion)
  53.     4.2.1 Oral
  54.     4.2.2 Intravenous
  55.     4.2.3 Subcutaneous
  56.   4.3 Healthcare, BY Indication (USD Billion)
  57.     4.3.1 Breast Cancer
  58.     4.3.2 Ovarian Cancer
  59.     4.3.3 Prostate Cancer
  60.     4.3.4 Pancreatic Cancer
  61.   4.4 Healthcare, BY Therapeutic Area (USD Billion)
  62.     4.4.1 Oncology
  63.     4.4.2 Hematology
  64.     4.4.3 Genetic Disorders
  65.   4.5 Healthcare, BY Region (USD Billion)
  66.     4.5.1 North America
  67.       4.5.1.1 US
  68.       4.5.1.2 Canada
  69.     4.5.2 Europe
  70.       4.5.2.1 Germany
  71.       4.5.2.2 UK
  72.       4.5.2.3 France
  73.       4.5.2.4 Russia
  74.       4.5.2.5 Italy
  75.       4.5.2.6 Spain
  76.       4.5.2.7 Rest of Europe
  77.     4.5.3 APAC
  78.       4.5.3.1 China
  79.       4.5.3.2 India
  80.       4.5.3.3 Japan
  81.       4.5.3.4 South Korea
  82.       4.5.3.5 Malaysia
  83.       4.5.3.6 Thailand
  84.       4.5.3.7 Indonesia
  85.       4.5.3.8 Rest of APAC
  86.     4.5.4 South America
  87.       4.5.4.1 Brazil
  88.       4.5.4.2 Mexico
  89.       4.5.4.3 Argentina
  90.       4.5.4.4 Rest of South America
  91.     4.5.5 MEA
  92.       4.5.5.1 GCC Countries
  93.       4.5.5.2 South Africa
  94.       4.5.5.3 Rest of MEA
  95. 5 SECTION V: COMPETITIVE ANALYSIS
  96.   5.1 Competitive Landscape
  97.     5.1.1 Overview
  98.     5.1.2 Competitive Analysis
  99.     5.1.3 Market share Analysis
  100.     5.1.4 Major Growth Strategy in the Healthcare
  101.     5.1.5 Competitive Benchmarking
  102.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  103.     5.1.7 Key developments and growth strategies
  104.       5.1.7.1 New Product Launch/Service Deployment
  105.       5.1.7.2 Merger & Acquisitions
  106.       5.1.7.3 Joint Ventures
  107.     5.1.8 Major Players Financial Matrix
  108.       5.1.8.1 Sales and Operating Income
  109.       5.1.8.2 Major Players R&D Expenditure. 2023
  110.   5.2 Company Profiles
  111.     5.2.1 AstraZeneca (GB)
  112.       5.2.1.1 Financial Overview
  113.       5.2.1.2 Products Offered
  114.       5.2.1.3 Key Developments
  115.       5.2.1.4 SWOT Analysis
  116.       5.2.1.5 Key Strategies
  117.     5.2.2 Bristol-Myers Squibb (US)
  118.       5.2.2.1 Financial Overview
  119.       5.2.2.2 Products Offered
  120.       5.2.2.3 Key Developments
  121.       5.2.2.4 SWOT Analysis
  122.       5.2.2.5 Key Strategies
  123.     5.2.3 Merck & Co. (US)
  124.       5.2.3.1 Financial Overview
  125.       5.2.3.2 Products Offered
  126.       5.2.3.3 Key Developments
  127.       5.2.3.4 SWOT Analysis
  128.       5.2.3.5 Key Strategies
  129.     5.2.4 Pfizer (US)
  130.       5.2.4.1 Financial Overview
  131.       5.2.4.2 Products Offered
  132.       5.2.4.3 Key Developments
  133.       5.2.4.4 SWOT Analysis
  134.       5.2.4.5 Key Strategies
  135.     5.2.5 Roche (CH)
  136.       5.2.5.1 Financial Overview
  137.       5.2.5.2 Products Offered
  138.       5.2.5.3 Key Developments
  139.       5.2.5.4 SWOT Analysis
  140.       5.2.5.5 Key Strategies
  141.     5.2.6 Novartis (CH)
  142.       5.2.6.1 Financial Overview
  143.       5.2.6.2 Products Offered
  144.       5.2.6.3 Key Developments
  145.       5.2.6.4 SWOT Analysis
  146.       5.2.6.5 Key Strategies
  147.     5.2.7 Eli Lilly and Company (US)
  148.       5.2.7.1 Financial Overview
  149.       5.2.7.2 Products Offered
  150.       5.2.7.3 Key Developments
  151.       5.2.7.4 SWOT Analysis
  152.       5.2.7.5 Key Strategies
  153.     5.2.8 AbbVie (US)
  154.       5.2.8.1 Financial Overview
  155.       5.2.8.2 Products Offered
  156.       5.2.8.3 Key Developments
  157.       5.2.8.4 SWOT Analysis
  158.       5.2.8.5 Key Strategies
  159.     5.2.9 GSK (GB)
  160.       5.2.9.1 Financial Overview
  161.       5.2.9.2 Products Offered
  162.       5.2.9.3 Key Developments
  163.       5.2.9.4 SWOT Analysis
  164.       5.2.9.5 Key Strategies
  165.   5.3 Appendix
  166.     5.3.1 References
  167.     5.3.2 Related Reports
  168. 6 LIST OF FIGURES
  169.   6.1 MARKET SYNOPSIS
  170.   6.2 NORTH AMERICA MARKET ANALYSIS
  171.   6.3 US MARKET ANALYSIS BY MECHANISM OF ACTION
  172.   6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
  173.   6.5 US MARKET ANALYSIS BY INDICATION
  174.   6.6 US MARKET ANALYSIS BY THERAPEUTIC AREA
  175.   6.7 CANADA MARKET ANALYSIS BY MECHANISM OF ACTION
  176.   6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  177.   6.9 CANADA MARKET ANALYSIS BY INDICATION
  178.   6.10 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA
  179.   6.11 EUROPE MARKET ANALYSIS
  180.   6.12 GERMANY MARKET ANALYSIS BY MECHANISM OF ACTION
  181.   6.13 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
  182.   6.14 GERMANY MARKET ANALYSIS BY INDICATION
  183.   6.15 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA
  184.   6.16 UK MARKET ANALYSIS BY MECHANISM OF ACTION
  185.   6.17 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
  186.   6.18 UK MARKET ANALYSIS BY INDICATION
  187.   6.19 UK MARKET ANALYSIS BY THERAPEUTIC AREA
  188.   6.20 FRANCE MARKET ANALYSIS BY MECHANISM OF ACTION
  189.   6.21 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
  190.   6.22 FRANCE MARKET ANALYSIS BY INDICATION
  191.   6.23 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA
  192.   6.24 RUSSIA MARKET ANALYSIS BY MECHANISM OF ACTION
  193.   6.25 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  194.   6.26 RUSSIA MARKET ANALYSIS BY INDICATION
  195.   6.27 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA
  196.   6.28 ITALY MARKET ANALYSIS BY MECHANISM OF ACTION
  197.   6.29 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
  198.   6.30 ITALY MARKET ANALYSIS BY INDICATION
  199.   6.31 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA
  200.   6.32 SPAIN MARKET ANALYSIS BY MECHANISM OF ACTION
  201.   6.33 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
  202.   6.34 SPAIN MARKET ANALYSIS BY INDICATION
  203.   6.35 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA
  204.   6.36 REST OF EUROPE MARKET ANALYSIS BY MECHANISM OF ACTION
  205.   6.37 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
  206.   6.38 REST OF EUROPE MARKET ANALYSIS BY INDICATION
  207.   6.39 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA
  208.   6.40 APAC MARKET ANALYSIS
  209.   6.41 CHINA MARKET ANALYSIS BY MECHANISM OF ACTION
  210.   6.42 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  211.   6.43 CHINA MARKET ANALYSIS BY INDICATION
  212.   6.44 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
  213.   6.45 INDIA MARKET ANALYSIS BY MECHANISM OF ACTION
  214.   6.46 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  215.   6.47 INDIA MARKET ANALYSIS BY INDICATION
  216.   6.48 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA
  217.   6.49 JAPAN MARKET ANALYSIS BY MECHANISM OF ACTION
  218.   6.50 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
  219.   6.51 JAPAN MARKET ANALYSIS BY INDICATION
  220.   6.52 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA
  221.   6.53 SOUTH KOREA MARKET ANALYSIS BY MECHANISM OF ACTION
  222.   6.54 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  223.   6.55 SOUTH KOREA MARKET ANALYSIS BY INDICATION
  224.   6.56 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA
  225.   6.57 MALAYSIA MARKET ANALYSIS BY MECHANISM OF ACTION
  226.   6.58 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  227.   6.59 MALAYSIA MARKET ANALYSIS BY INDICATION
  228.   6.60 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA
  229.   6.61 THAILAND MARKET ANALYSIS BY MECHANISM OF ACTION
  230.   6.62 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
  231.   6.63 THAILAND MARKET ANALYSIS BY INDICATION
  232.   6.64 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA
  233.   6.65 INDONESIA MARKET ANALYSIS BY MECHANISM OF ACTION
  234.   6.66 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  235.   6.67 INDONESIA MARKET ANALYSIS BY INDICATION
  236.   6.68 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA
  237.   6.69 REST OF APAC MARKET ANALYSIS BY MECHANISM OF ACTION
  238.   6.70 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
  239.   6.71 REST OF APAC MARKET ANALYSIS BY INDICATION
  240.   6.72 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA
  241.   6.73 SOUTH AMERICA MARKET ANALYSIS
  242.   6.74 BRAZIL MARKET ANALYSIS BY MECHANISM OF ACTION
  243.   6.75 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
  244.   6.76 BRAZIL MARKET ANALYSIS BY INDICATION
  245.   6.77 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA
  246.   6.78 MEXICO MARKET ANALYSIS BY MECHANISM OF ACTION
  247.   6.79 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
  248.   6.80 MEXICO MARKET ANALYSIS BY INDICATION
  249.   6.81 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA
  250.   6.82 ARGENTINA MARKET ANALYSIS BY MECHANISM OF ACTION
  251.   6.83 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  252.   6.84 ARGENTINA MARKET ANALYSIS BY INDICATION
  253.   6.85 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA
  254.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY MECHANISM OF ACTION
  255.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  256.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
  257.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA
  258.   6.90 MEA MARKET ANALYSIS
  259.   6.91 GCC COUNTRIES MARKET ANALYSIS BY MECHANISM OF ACTION
  260.   6.92 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
  261.   6.93 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
  262.   6.94 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA
  263.   6.95 SOUTH AFRICA MARKET ANALYSIS BY MECHANISM OF ACTION
  264.   6.96 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  265.   6.97 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
  266.   6.98 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA
  267.   6.99 REST OF MEA MARKET ANALYSIS BY MECHANISM OF ACTION
  268.   6.100 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  269.   6.101 REST OF MEA MARKET ANALYSIS BY INDICATION
  270.   6.102 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA
  271.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  272.   6.104 RESEARCH PROCESS OF MRFR
  273.   6.105 DRO ANALYSIS OF HEALTHCARE
  274.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  275.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  276.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  277.   6.109 HEALTHCARE, BY MECHANISM OF ACTION, 2024 (% SHARE)
  278.   6.110 HEALTHCARE, BY MECHANISM OF ACTION, 2024 TO 2035 (USD Billion)
  279.   6.111 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
  280.   6.112 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
  281.   6.113 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
  282.   6.114 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
  283.   6.115 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
  284.   6.116 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
  285.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  286. 7 LIST OF TABLES
  287.   7.1 LIST OF ASSUMPTIONS
  288.     7.1.1
  289.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  290.     7.2.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  291.     7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  292.     7.2.3 BY INDICATION, 2025-2035 (USD Billion)
  293.     7.2.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  294.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  295.     7.3.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  296.     7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  297.     7.3.3 BY INDICATION, 2025-2035 (USD Billion)
  298.     7.3.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  299.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  300.     7.4.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  301.     7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  302.     7.4.3 BY INDICATION, 2025-2035 (USD Billion)
  303.     7.4.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  304.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  305.     7.5.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  306.     7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  307.     7.5.3 BY INDICATION, 2025-2035 (USD Billion)
  308.     7.5.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  309.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  310.     7.6.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  311.     7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  312.     7.6.3 BY INDICATION, 2025-2035 (USD Billion)
  313.     7.6.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  314.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  315.     7.7.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  316.     7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  317.     7.7.3 BY INDICATION, 2025-2035 (USD Billion)
  318.     7.7.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  319.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  320.     7.8.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  321.     7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  322.     7.8.3 BY INDICATION, 2025-2035 (USD Billion)
  323.     7.8.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  324.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  325.     7.9.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  326.     7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  327.     7.9.3 BY INDICATION, 2025-2035 (USD Billion)
  328.     7.9.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  329.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  330.     7.10.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  331.     7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  332.     7.10.3 BY INDICATION, 2025-2035 (USD Billion)
  333.     7.10.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  334.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  335.     7.11.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  336.     7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  337.     7.11.3 BY INDICATION, 2025-2035 (USD Billion)
  338.     7.11.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  339.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  340.     7.12.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  341.     7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  342.     7.12.3 BY INDICATION, 2025-2035 (USD Billion)
  343.     7.12.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  344.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  345.     7.13.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  346.     7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  347.     7.13.3 BY INDICATION, 2025-2035 (USD Billion)
  348.     7.13.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  349.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  350.     7.14.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  351.     7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  352.     7.14.3 BY INDICATION, 2025-2035 (USD Billion)
  353.     7.14.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  354.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  355.     7.15.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  356.     7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  357.     7.15.3 BY INDICATION, 2025-2035 (USD Billion)
  358.     7.15.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  359.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  360.     7.16.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  361.     7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  362.     7.16.3 BY INDICATION, 2025-2035 (USD Billion)
  363.     7.16.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  364.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  365.     7.17.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  366.     7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  367.     7.17.3 BY INDICATION, 2025-2035 (USD Billion)
  368.     7.17.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  369.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  370.     7.18.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  371.     7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  372.     7.18.3 BY INDICATION, 2025-2035 (USD Billion)
  373.     7.18.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  374.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  375.     7.19.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  376.     7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  377.     7.19.3 BY INDICATION, 2025-2035 (USD Billion)
  378.     7.19.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  379.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  380.     7.20.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  381.     7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  382.     7.20.3 BY INDICATION, 2025-2035 (USD Billion)
  383.     7.20.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  384.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  385.     7.21.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  386.     7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  387.     7.21.3 BY INDICATION, 2025-2035 (USD Billion)
  388.     7.21.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  389.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  390.     7.22.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  391.     7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  392.     7.22.3 BY INDICATION, 2025-2035 (USD Billion)
  393.     7.22.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  394.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  395.     7.23.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  396.     7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  397.     7.23.3 BY INDICATION, 2025-2035 (USD Billion)
  398.     7.23.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  399.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  400.     7.24.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  401.     7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  402.     7.24.3 BY INDICATION, 2025-2035 (USD Billion)
  403.     7.24.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  404.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  405.     7.25.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  406.     7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  407.     7.25.3 BY INDICATION, 2025-2035 (USD Billion)
  408.     7.25.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  409.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  410.     7.26.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  411.     7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  412.     7.26.3 BY INDICATION, 2025-2035 (USD Billion)
  413.     7.26.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  414.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  415.     7.27.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  416.     7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  417.     7.27.3 BY INDICATION, 2025-2035 (USD Billion)
  418.     7.27.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  419.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  420.     7.28.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  421.     7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  422.     7.28.3 BY INDICATION, 2025-2035 (USD Billion)
  423.     7.28.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  424.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  425.     7.29.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  426.     7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  427.     7.29.3 BY INDICATION, 2025-2035 (USD Billion)
  428.     7.29.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  429.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  430.     7.30.1 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
  431.     7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  432.     7.30.3 BY INDICATION, 2025-2035 (USD Billion)
  433.     7.30.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  434.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  435.     7.31.1
  436.   7.32 ACQUISITION/PARTNERSHIP
  437.     7.32.1

Healthcare Market Segmentation

Healthcare By Mechanism of Action (USD Billion, 2025-2035)

  • PARP Inhibition
  • DNA Damage Response
  • Cell Cycle Checkpoint Regulation

Healthcare By Administration Route (USD Billion, 2025-2035)

  • Oral
  • Intravenous
  • Subcutaneous

Healthcare By Indication (USD Billion, 2025-2035)

  • Breast Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Pancreatic Cancer

Healthcare By Therapeutic Area (USD Billion, 2025-2035)

  • Oncology
  • Hematology
  • Genetic Disorders

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions